key: cord-0077546-kzh7rwoi
authors: Delaugerre, Constance; Assoumou, Lambert; Maylin, Sarah; Minier, Marine; Gabassi, Audrey; Genin, Michèle; Beniguel, Lydie; Ghosn, Jade; de Lamballerie, Xavier; El Mouhebb, Mayssam; Costagliola, Dominique; Carrat, Fabrice; Molina, Jean-Michel
title: SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 – A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts
date: 2022-04-12
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac188
sha: fcdbd4a6631974adcbd75a3582f683a053c4ee33
doc_id: 77546
cord_uid: kzh7rwoi

The potential preventive efficacy of tenofovir/emtricitabine on SARS-CoV-2 infection was assessed in HIV pre-exposition prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 IgG between May and October 2020 was similar in PrEP users and in a matched population-based cohort suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.

CoV-2), has been defined as a pandemic around the world by the World Health Organization (WHO). The 3 SARS-CoV-2 is a coronavirus, as SARS-CoV and MERS-CoV, that is a positive-sense single-strand RNA virus 4 with replication mechanism requiring a RNA-dependent RNA polymerase. Therefore, at the beginning of 5 the pandemic, known drugs targeting viral RdRp of SARS-CoV or other coronaviruses were repurposed 6 due to the urgent need for an antiviral therapy for the new member of the family, SARS-CoV-2. 7

Tenofovir disoproxil fumarate (TDF) one of the components of pre-exposition prophylaxis (PrEP), is 8 transformed intracellularly in its active form, tenofovir-triphosphate which inhibits the activity of viral 9 polymerase in HIV and HBV and has also shown an antiviral activity on SARS-CoV-2 in vitro and in ferret 10

Different observational studies, performed between February and September 2020, report matter of 12 debate regarding the potential benefit of TDF to reduce the incidence of SARS-CoV-2 infection or COVID-13 19-related morbi-mortality in persons using TDF-based regimen as pre-exposition prophylaxis (PrEP) or 14 treatment for HIV-infected patients [4] [5] [6] [7] [8] . 15

To assess the potential preventive impact of TDF/emtricitabine (FTC) on SARS-CoV-2 acquisition, we 16 compared during the same time period the seroprevalence of SARS-CoV-2 IgG antibodies rates in male 17 participants of the PREVENIR cohort study of PrEP implementation in Paris area, with participants using 18 intermittent or daily TDF/FTC to that of male participants enrolled in the SAPRIS-sero study in Paris area, 19

France. 20

Between May 1 st and October 31, 2020, male participants using either daily or on demand PrEP with 3 TDF/FTC enrolled in the PREVENIR study conducted in Paris area, France, and who had a stored serum 4 sample available were included in this study [9] . Participants non-exposed to TDF/FTC were male 5 participants living in Paris area included in the SAPRIS-Sero national survey that estimate SARS-CoV-2 6 antibodies prevalence in the French general population [10]. 7

Based on the factors associated with the risk of SARS-CoV-2 infection in the initial analysis of the SAPRIS 8 cohort [11] and on available data in both studies, the matching criteria were age (± 5 years), socio-9 occupational category and date of sampling (± 1 month). Ethical approval and written or electronic 10 informed consent were obtained from each participant before enrolment in both original cohorts. When 11 PREVENIR participants could not be matched on the 3 criteria, they were matched on age and socio-12 occupational category then age and sampling date, then on age. 13

Ethical approval and written or electronic informed consent were obtained from each participant before 15 enrolment in the original cohort. The SAPRIS-SERO study was approved by the Sud-Mediterranée III 16 ethics committee (approval #20.04.22.74247). The PREVENIR study was approved by the CPP Paris Ile de 17

France IV ethics committee (NCT03113123 and EudraCT 2016-A01577-44). 18

A systematic serology was performed in all participants in both cohorts. In the PREVENIR cohort, the 20 SARS-CoV-2 IgG determination was performed using the SARS-CoV-2 IgG II Quantitative antibody ELISA 21 assay (Architect, Abbott, France) on frozen serum. It is a chemiluminescent microparticle immunoassay 22

(CMIA) used for the qualitative and quantitative determination of IgG antibodies against the spike 1 receptor-binding domain (RBD) of SARS-CoV-2. The analytical measurement interval is stated as 21 to 2 40,000 AU/ml, and positivity cutoff is >50 AU/ml (and low positive <100 AU/ml). In the SAPRIS-Sero 3 cohorts, we used the Anti-SARS-CoV-2 IgG ELISA (Euroimmun, Germany) that provide semi-quantitative 4 serology results against the S1 domain of the spike protein of SARS-CoV-2 [10].. Samples with an ELISA-S 5 test optical density ratio of <0.8 as considered as negative, > 0.8 to <1.0 as undetermined and > 1.0 as 6 positive. For both tests, the sensitivity (based on 14-day post-positive reverse transcription-PCR 7 samples) and specificity were > 98% and > 99%, respectively [12] . 8

Because only age, socio-professional category, and date of sampling were collected in both studies and 10 used as matching criteria, we did not compare these factors between the two study populations. for the whole population in PREVENIR and SAPRIS-Sero cohorts, respectively (Odds-ratio: 1.17, 95% 4 confidence interval 0.86-1.60). The seroprevalence rates were similar among daily or on-demand users 5 (9.9% vs 11.7%, Fisher's Exact p=0.4095). Sensitivity analyses (restricted to fully matched participants or 6 considering undetermined as positive serology) led to similar results. 7

We evaluated whether the use of tenofovir/emtricitabine as HIV pre-exposure prophylaxis in HIV-9 negative male included in the PREVENIR study could reduce the prevalence of SARS-CoV-2 10 seroconversion as compared to a matched to a control cohort of male from the general population not 11 using PrEP in Paris (from SAPRIS survey). The SARS-CoV-2 IgG seroprevalence was 10.3% in the 12 PREVENIR study and 9.2% in the SAPRIS survey among 844 male individuals between May to October 13 2020 in Paris region. This prevalence of 10% was those found for the Paris region corresponding to one Baseline characteristic of patients as age and comorbidities were not accounted for in these studies, 23

while each has been identified as an independent risk factor for poorer outcomes with COVID-19 [13] 1 and can influence the choice of regimen, for instance not using TDF in patients with renal impairment. 2

Recently, an updated of the study from del Amo demonstrated that TDF has a protective effect 3 restricted to individuals aged 50 years and older [14] . Moreover, during the first wave, most SARS-CoV-2 4 PCR tests were done only in symptomatic or even hospitalized individuals that could be lead to bias. 5

One study from May to June 2020 in Spain assessed the effect of tenofovir-emtricitabine use as HIV PrEP 6 in HIV-negative persons showing a higher seroprevalence to SARS-CoV-2 IgG anti nucleocapsid than in 7 persons without PrEP (15% versus 9.2%, p=0.026) [7] . Interestingly there were no significant differences 8 in the sex, presence of comorbidities, occupational exposure, or exposure by households with confirmed 9 cases. However, the population of PrEP user and those who did not take PrEP was not adjusted, in 10 contrary to our study in which we selected factors (age, socio-occupational category and sampling date) 11 that were found associated with the risk of SARS-CoV-2 infection in the initial analysis of the SAPRIS 12 cohort [11] . 13

Our study has some limitations. First, we did not collected exhaustively information about positive SARS-14

CoV-2 PCR and COVID-19-like symptoms to determine the effect TDF/FTC on SARS-CoV-2 infection since 15 some individuals might become infected without seroconversion. Our study could not explore the effect 16 of TDF on illness but only on SARS-CoV-2 infection. 17

Second, the factors of exposition to SARS-CoV-2 were not collected. Third, we used two serological tests 18 from different manufacturers to compare the IgG detection but the viral target is the same and 19 sensitivity and specificity were comparable [12] . A lower sensitivity of the test used in the SAPRIS-Sero 20 cohort compared with the test used in the PREVENIR study would not affect our conclusions as it would 21 decrease the difference in measured seroprevalence. 22

To conclude, the similar seroprevalence of SARS-CoV-2 IgG found in participants using or not TDF/FTC as 23 HIV PrEP suggested that TDF/FTC has no role in reducing SARS-CoV-2 acquisition. 

A library of nucleotide analogues terminate RNA synthesis 2 catalyzed by polymerases of coronaviruses that cause SARS and COVID-19

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico 5 perspective

CoV-2 Infection in Ferrets

Incidence and Severity of COVID-19 in HIV-Positive 9

Persons Receiving Antiretroviral Therapy : A Cohort Study

Prevalence and factors associated with 11

SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

Western Cape Department of Health in collaboration with the National Institute for 14

Risk Factors for Coronavirus Disease

Death in a Population Cohort Study from the Western Cape Province, South Africa

Preventive Efficacy of Tenofovir/Emtricitabine Against 18

Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users

SARS-CoV-2 infection among adults in three regions of France following the first lockdown and 4 associated risk factors: a multicohort study

Incidence and risk factors of COVID-19-like 6 symptoms in the French general population during the lockdown period: a multi-cohort study

Assessment of SARS-CoV-2 serological tests for the 9 diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated 10 immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay

Diabetes, obesity, 13 hypertension and risk of severe COVID-19: a protocol for systematic review and meta-analysis

PEOPLE WITH HIV INFECTION. Abstracts From the 2022 Conference on 17